Firazyr Approved for Rare Swelling Disease
Hereditary angiodema can cause tissue in limbs, airway to swell
THURSDAY, Aug. 25 (HealthDay News) -- Firazyr (icatibant) has been approved by the U.S. Food and Drug Administration to treat acute (severe) attacks of hereditary angiodema (HAE) in adults.
The rare genetic condition is caused by low amounts of a protein called C1 inhibitor. Fewer than 30,000 people in the United States have the condition, the agency said in a news release. It causes potential symptoms including rapid swelling of the hands, feet, limbs, face, intestines and voice pipe.
Airway swelling puts victims at risk of suffocation, the FDA said.
The drug's safety and effectiveness were evaluated in clinical testing involving 225 patients. Symptom relief took an average of two hours among people who took the drug, versus almost 20 hours among those who took a placebo, the agency said.
Common side effects included injection site reactions, fever, an increase in liver enzymes, dizziness and rash.
Two other drugs, Berinert and Kalbitor, were approved previously to treat symptoms of HAE, the FDA said.
Firazyr is marketed by Shire Human Genetic Therapies, based in Cambridge, Mass.
The U.S. Hereditary Angiodema Association has more about this condition.Scott Roberts Related Articles
- FDA Approves Hard-to-Abuse Narcotic Painkiller
July 24, 2014
- Tough-to-Abuse Formulation of Oxycodone Approved
July 24, 2014
Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.
Copyright © 2011 HealthDay. All rights reserved.